Trusted Resources: News & Meetings
Latest announcements and gatherings
Sanfilippo Ideal for FDA’s Accelerated Approval Pathway, Foundation Says
The Cure Sanfilippo Foundation is encouraging the U.S. Food & Drug Administration (FDA) to consider Sanfilippo syndrome as a candidate for the agency’s accelerated approval pathway. According to a recent foundation-led study, families of Sanfilippo children are willing to accept modest treatment benefits even if they come with risks.
“Doing nothing is the biggest risk in Sanfilippo!” Glenn O’Neill, foundation president and father to a Sanfilippo child, said in a press release. His statement came at the end of a presentation Oct. 20 at the 13th Annual Rare Disease Scientific Workshop.
The FDA’s Accelerated Approval Program allows for earlier approval of therapies that treat serious conditions and fill an unmet medical need. Sanfilippo syndrome, or mucopolysaccharidosis type III (MPS III), is a rare genetic disorder characterized by the mutations in genes that encode enzymes that break down the complex sugar molecule known as heparan sulfate.
BookmarkRelated Content
-
Q&A Coronavirus and Sanfilippo Syndrome: Dr. Heather Lauhttps://www.youtube.com/watch?v=Dn3XZiHA...
-
Julie Eisengart, PhD, LPDr. Julie Eisengart is an Associate Prof...
-
Johns Hopkins – Lysosomal Storage Disease CenterLysosomes are packets of enzymes or othe...
-
Clinical and Event-Based Outcomes of Patients With Mucopolysaccharidosis VI Receiving Enzyme Replacement Therapy in ...The objective of this study was to descr...
-
Treatment Team of Specialists for Sanfilippo SyndromeSanfilippo syndrome can affect many syst...
-
Music Therapy and Sanfilippo Syndrome: an Analysis of Psychological and Physiological Variables of Three Case Studie...Mucopolysaccharidosis type III (MPS III)...
-
Mucopolysaccharidosis III: Molecular Basis and TreatmentMucopolysaccharidoses (MPSs) are known a...
Powered by
